Phaarmasia Ltd

Phaarmasia Ltd is rated Sell by MarketsMOJO, with this rating last updated on 14 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 August 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trend, and technical outlook.

Phaarmasia Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 14 July 2026. This shift reflects a complex interplay of deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some attractive valuation metrics. The company’s Mojo Score has declined to 44.0, signalling caution for investors amid volatile price action and operational challenges.

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 9 July 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends despite recent flat quarterly results and ongoing operational challenges.

Phaarmasia Ltd is rated Sell by MarketsMOJO, with this rating last updated on 11 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 July 2026, providing investors with the latest insights into its performance and outlook.

Phaarmasia Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a complex interplay of deteriorating technical indicators, flat financial performance, and valuation considerations, despite the company’s impressive long-term returns and attractive price-to-book ratio.

Phaarmasia Ltd has seen its investment rating upgraded from Sell to Hold as of 8 June 2026, reflecting a nuanced shift in its overall outlook. This change is driven by a combination of factors including improved valuation metrics, stable quality indicators, mixed financial trends, and evolving technical signals. Despite recent flat quarterly performance and operational challenges, the stock’s long-term returns and relative valuation have prompted a reassessment of its market stance.

Phaarmasia Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the company’s valuation metrics suggest a more compelling price entry point relative to its historical averages and peer group, warranting a closer examination for investors seeking micro-cap opportunities in Pharmaceuticals & Biotechnology.

Phaarmasia Limited (NSE: PHAARMASIA, BSE: 523620), a micro-cap pharmaceutical manufacturer specialising in hormonal contraceptive tablets, reported a troubling quarter-on-quarter deterioration in Q4 FY26, posting a net loss of ₹0.70 crores against a profit of ₹16.27 crores in the previous quarter. The Hyderabad-based company, with a modest market capitalisation of ₹53.00 crores, saw its net sales plummet 51.84% sequentially to ₹7.73 crores, raising serious questions about revenue sustainability and operational stability.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. While the rating was revised earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 29 May 2026, providing investors with an up-to-date view of the company’s position in the Pharmaceuticals & Biotechnology sector.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 18 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Phaarmasia Ltd has witnessed a significant improvement in its valuation parameters, shifting from an 'attractive' to a 'very attractive' grade, reflecting a notable change in investor sentiment. Despite a recent 3.5% dip in its share price, the micro-cap pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now position it favourably against both historical benchmarks and peer averages, signalling potential value opportunities for discerning investors.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 April 2026, providing investors with the latest insights into its performance and outlook.

Phaarmasia Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a renewed price appeal for investors. This micro-cap pharmaceutical player’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside other key metrics, suggest a more favourable investment proposition compared to its historical averages and peer group benchmarks.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 April 2026, providing investors with the latest insights into its performance and outlook.

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 February 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 02 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.